...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Free
Message: Kidney Week 2019 FR-PO317 From Barsax on another board

https://www.asn-online.org/education/kidneyweek/archives/

 
you can download the 1300 page .pdf file.  The relevant info is FR PO317
 
Its under "Kidney Week 2019 Abstracts" 
 
its on Friday, and the poster # is 317
 
I found this on page 518... 
 
 FR-PO317 Poster Friday CKD: Clinical, Outcomes, Trials - II 
 
Association of Serum Alkaline Phosphatase with CKD and Cognitive Function in Patients with Diabetes and Acute Coronary Syndrome 
 
Mathias Haarhaus, 1,2 Kausik K. Ray,3 Gregory G. Schwartz,4 Ewelina Kulikowski,5 Jan O. Johansson,6 Michael Sweeney, 6 Aziz Khan,5 ChristopherHalliday,5 KennethE.Lebioda,5 NormanC.Wong,5 BengtWinblad,7 Henrik Zetterberg,8 Vincent Brandenburg,9 Srinivasan Beddhu,10 Marcello Tonelli,11 Carmine Zoccali,12 Kamyar Kalantar-Zadeh.13,14 1 Division of Renal Medicine and Baxter Novum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 2 Diaverum Sweden, Stockholm, Sweden; 3 Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom; 4 School of Medicine, University of Colorado, Aurora, CO; 5 Resverlogix Corp., Calgary, AB, Canada; 6 Resverlogix Inc., San Francisco, CA; 7 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; 8 Department of Psychiatry and Neurochemistry- Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 9 Department of Cardiology and Nephrology, Rhein-Maas-Klinikum, Würselen, Germany; 10Division of Nephrology and Hypertension and Medical Service, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT; 11Department of Medicine, University of Calgary, Calgary, AB, Canada; 12CNR IFC, Clinical Epidemiology of Renal Diseases and Hypertension, Reggio Calabria, Italy; 13Division of Nephrology and Hypertension, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, School of Medicine, Orange, CA; 14Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA.
 
Background: Patients with diabetes and chronic kidney disease (CKD) have increased risk for cardiovascular disease events and vascular dementia. Alkaline phosphatase (ALP) is a risk marker and possible risk mediator for cardiovascular (CV) disease, Alzheimer’s disease and vascular dementia. ALP has been reported to cross the blood brain barrier and to predict cognitive risk in CKD patients, potentially via vascular mechanisms or dephosphorylation of tau. Apabetalone is a bromodomain and extraterminal (BET) inhibitor selective for bromodomain 2, lowers ALP in a dose-response fashion and is being evaluated for prevention of CV disease events in the phase 3 BETonMACE trial. We examined baseline data from that trial to define the associations of ALP with CKD and cognitive function. 
 
Methods: BETonMACE compares cardiovascular outcomes with apabetalone or placebo in 2425 patients with diabetes and acute coronary syndrome. CKD was defined by eGFR < 60 mL/min/1.73m2 . Cognition was assessed by the Montreal Cognitive Assessment tool (MoCA) in patients aged 70 and older at baseline (n=467) including in CKD patients (n=86). 
 
Results: CKD was present in 11% (n=263) and was associated with age, female sex, longer history of diabetes, and higher ALP. Approximately half of the population showed MoCA score <26 suggesting early cognitive impairment. Lower MoCA score was associated with: a) higher ALP, and, b) with presence of CKD.
 

 

Conclusions: Elevated ALP is associated with poorer cognitive function and greater prevalence of CKD. Apabetalone, which lowers ALP, is being evaluated for effects on CV events, CKD, and cognitive function in the phase 3 BETonMACE trial reporting 2019.
Share
New Message
Please login to post a reply